

Wyoming Drug Utilization Review
P & T Committee Meeting
November 8, 2018
Laramie County Community College, CCI 130
Cheyenne, Wyoming
10 am - 1 pm

AGENDA

- I. Introduction and Announcements
- II. Approval of minutes of August 9, 2018
- III. Department of Health
 - A. Pharmacy Program Manager Report
 - B. Medical Director Report
 - C. DUR Manager Report
- IV. Old Business
 - A. Suboxone
 - B. Antipsychotic dose limits
- V. New Business
 - A. PA Criteria
 - 1. Review existing PA criteria
 - i. Cimzia (new indication and pregnancy info)
 - ii. Triptans (FYI)
 - 2. New Drugs
 - i. Orilissa
 - ii. Perseris (dose)
 - iii. Mulpleta
 - iv. Ilumya
 - v. Takhzyro
 - vi. Ajovy
 - vii. Lucemyra
 - viii. Aimovig
 - ix. Kevzara
 - x. Palyntiq
 - xi. Olumiant
 - xii. Baxdela
 - 3. Determine need for criteria
 - i. Gabapentin and Lyrica – dose limits and concurrent use
 - ii. Antipsychotics – concurrent use of injectable and oral
- VI. Other
 - A. 2019 Draft PDL
- VII. Open Comments
- VIII. Executive session

The business portion of the meeting will be from 10 am to approximately 11:30 am. (Agenda items I - VII). The executive session (item VIII) begins at approximately 11:45 am. Committee members who are unable to attend please inform Laura at lgm@uwyo.edu or 307-766-6750.